**Introduction**

Molecular MD is an acknowledged leader in genomics and is renowned for its extensive experience in the development and implementation of applications, not to mention its reputation for the highest quality genetic testing. A recent study has demonstrated that its BRAF V600 AS-PCR test can provide meaningful information to patients and physicians. This is a significant step forward in the treatment of patients with tumors expressing V600 mutations. The BRAF V600 AS-PCR test can be used to assess the presence of the most common tumor suppressor protein.

**Materials & Methods**

- **Amplification**:
  - V600E (A, 42
  - V600G (A, 42
  - V600R (A, 42
  - V600S (A, 42
  - V600W (A, 42

- **BRAF V600 AS-PCR Plasma-Based Assay Summary**
  - **Concordance**:
    - **Concordance of BRAF V600 AS-PCR and SNaPshot results for Plasma Samples**
      - **Table 4**: Concordance of BRAF V600 AS-PCR and SNaPshot results for Plasma Samples
        - **Table 5**: Good precision was observed using independent plasma DNA extractions and PCR runs with 2 operators.

- **Comparison of BRAF V600 AS-PCR and SNaPshot results for Plasma Samples**
  - **Table 6**: Comparison of BRAF V600 AS-PCR and SNaPshot results for Plasma Samples

- **Future directions**
  - The BRAF V600 AS-PCR assay is being evaluated for the detection of activating mutations in BRAF V600 AS-PCR and SNaPshot results for Plasma Samples.

- **References**

**Conclusions**

- **The BRAF V600 AS-PCR assay is being evaluated for the detection of activating mutations in BRAF V600 and SNaPshot results for Plasma Samples.**

For further information please contact info@molmd.com or visit www.molmd.com.